Ascendis Pharma Added to Citi Focus List, Ionis Removed
Investing.com - Ascendis Pharma (NASDAQ:ASND) AS reported on Wednesday second quarter earnings that beat analysts' forecasts and revenue that topped expectations. Ascendis...
Ascendis Pharma (NASDAQ:ASND) reported Q2 EPS of EUR(1.46).
Remember back in February, when we were worried about a market correction? Back when the NASDAQ dipped 10% from its peak… Yeah, well, never mind about that. Markets are up,...
Investors are always looking for stocks that are poised to beat at earnings season and Ascendis Pharma (NASDAQ:ASND) A/S ASND may be one such company. The firm has earnings coming...
BioMarin Pharmaceutical (NASDAQ:BMRN) Inc. BMRN filed a new drug application (NDA) for vosoritide to the FDA to treat children with achondroplasia, the most common form of dwarfism...
ASCENDIS PHARMA A/S is a Danish-based biopharmaceutical company, which is involved in manufacture products for rare diseases. The Company utilizes its TransCon technologies for treatment, which can be applied to existing drug therapies, including proteins, peptides and small molecules, to create prodrugs. The Company is headquartered in Copenhagen, Denmark with offices in Heidelberg, Germany and Palo Alto, California.
|Average||146.14 (+46.20% Upside)|
|No. of Analysts||14|